Pierre G Coulie

List of Publications by Year
in descending order

18	2,195	623734 14	940533 16
papers	citations	h-index	g-index

18	18	18	3053
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blocking GARP-mediated activation of TGF-Î²1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice. Cancer Immunology, Immunotherapy, 2022, , 1.	4.2	2
2	Pandemic chilblains: Are they SARS-CoV-2-related or not?. Clinical Immunology, 2022, 237, 108984.	3.2	0
3	Combined Blockade of GARP:TGF-Î²1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP+ Blood Vessels in Mouse MC38 Tumors. Frontiers in Immunology, 2021, 12, 704050.	4.8	11
4	Selective inhibition of TGF-Î²1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nature Communications, 2020, 11, 4545.	12.8	94
5	Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE, 2019, 14, e0225748.	2.5	20
6	Structural basis of latent TGF-Î²1 presentation and activation by GARP on human regulatory T cells. Science, 2018, 362, 952-956.	12.6	103
7	A new transcript in the TCRB locus unveils the human ortholog of the mouse preâ€DÃŸ1 promoter. Immunity, Inflammation and Disease, 2017, 5, 346-354.	2.7	0
8	Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin Î±VÎ²8. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10161-E10168.	7.1	85
9	Monoclonal antibodies against GARP/TGF-Î²1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine, 2015, 7, 284ra56.	12.4	130
10	Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery. Annals of Surgical Oncology, 2013, 20, 650-660.	1.5	126
11	Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Medical Hypotheses, 2013, 81, 707-712.	1.5	24
12	Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. Cancer Immunology, Immunotherapy, 2011, 60, 1153-1160.	4.2	57
13	Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases. Cancer Research, 2011, 71, 1253-1262.	0.9	176
14	Membrane protein GARP is a receptor for latent TGFâ€Î²2 on the surface of activated human Treg. European Journal of Immunology, 2009, 39, 3315-3322.	2.9	215
15	HUMAN T CELL RESPONSES AGAINST MELANOMA. Annual Review of Immunology, 2006, 24, 175-208.	21.8	596
16	High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. Journal of Experimental Medicine, 2005, 201, 241-248.	8.5	212
17	Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. Journal of Experimental Medicine, 2005, 201, 249-257.	8.5	224
18	Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. International Journal of Cancer, 1992, 50, 289-297.	5.1	120